one8zero8 LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 6,477 shares of the medical research company's stock, valued at approximately $3,247,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. High Note Wealth LLC grew its stake in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after buying an additional 29 shares in the last quarter. Swiss RE Ltd. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $28,000. Legacy Wealth Managment LLC ID grew its position in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after acquiring an additional 22 shares in the last quarter. Birchwood Financial Partners Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter valued at $29,000. Finally, Core Wealth Advisors LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at about $30,000. Hedge funds and other institutional investors own 89.23% of the company's stock.
Insider Transactions at Thermo Fisher Scientific
In other news, CAO Joseph R. Holmes sold 420 shares of the business's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares of the company's stock, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Lisa P. Britt sold 11,440 shares of the firm's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares of the company's stock, valued at $9,064,366.08. The trade was a 43.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 63,493 shares of company stock worth $37,657,681. Corporate insiders own 0.33% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on TMO shares. Weiss Ratings upgraded Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, July 14th. Barclays boosted their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Royal Bank Of Canada increased their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research report on Friday, July 24th. HSBC lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Finally, Sanford C. Bernstein began coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They set a "market perform" rating and a $520.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $619.41.
View Our Latest Research Report on Thermo Fisher Scientific
Thermo Fisher Scientific Trading Up 2.4%
NYSE:TMO opened at $628.24 on Friday. The firm has a market capitalization of $232.29 billion, a P/E ratio of 33.79, a P/E/G ratio of 2.50 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a fifty day moving average of $539.33 and a 200 day moving average of $508.86. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company's revenue was up 10.5% on a year-over-year basis. During the same quarter last year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.
Thermo Fisher Scientific Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.11%.
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report